Compare ANAB & FOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANAB | FOR |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2015 | 2007 |
| Metric | ANAB | FOR |
|---|---|---|
| Price | $64.27 | $25.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $70.60 | $31.75 |
| AVG Volume (30 Days) | ★ 439.6K | 118.1K |
| Earning Date | 05-25-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | $234,603,000.00 | ★ $1,662,400,000.00 |
| Revenue This Year | N/A | $0.52 |
| Revenue Next Year | $43.04 | $7.72 |
| P/E Ratio | ★ N/A | $83.10 |
| Revenue Growth | ★ 157.01 | 10.14 |
| 52 Week Low | $15.32 | $18.00 |
| 52 Week High | $66.66 | $30.74 |
| Indicator | ANAB | FOR |
|---|---|---|
| Relative Strength Index (RSI) | 66.99 | 35.01 |
| Support Level | $43.67 | $25.25 |
| Resistance Level | N/A | $26.00 |
| Average True Range (ATR) | 3.71 | 0.88 |
| MACD | 0.75 | -0.45 |
| Stochastic Oscillator | 86.73 | 19.61 |
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. the company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.